Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient

被引：2
|
作者：
Ghosn, Marwan [1 ]
Dagher, Alain [1 ]
El-Karak, Fadi [1 ]
机构：
[1] St Joseph Univ, Dept Hematol Oncol, Fac Med, 894 Blvd Alfred Naccache,Bldg Sehanoui,5th Floor, Beirut, Lebanon
来源：
JOURNAL OF BIOMEDICAL RESEARCH | 2015年 / 29卷 / 05期
关键词：
prostate-specific antigen; doubling time; prostate cancer; cabazitaxel; docetaxel;
D O I：
10.7555/JBR.28.20130148
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.
引用
收藏
页码：420 / 422
页数：3
相关论文
共 50 条
  • [41] Marked Response to 177Lu Prostate-Specific Membrane Antigen Treatment in Patient With Metastatic Prostate Cancer
    Soydal, Cigdem
    Ozkan, Elgin
    Akyurek, Serap
    Kucuk, Nuriye Ozlem
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (02) : 159 - 160
  • [42] Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
    Freedland, Stephen J.
    Ramaswamy, Krishnan
    Huang, Ahong
    Sandin, Rickard
    Mardekian, Jack
    Schultz, Neil M.
    Janjan, Nora
    George, Daniel J.
    CLINICAL GENITOURINARY CANCER, 2023, 21 (04) : 419 - 429
  • [43] Value of mitoxantrone in hormone-resistant metastatic prostate cancer - Commentary
    Coulange, C
    PROGRES EN UROLOGIE, 2002, 12 (01): : 41 - 41
  • [44] Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
    Armstrong, Andrew J.
    Garrett-Mayer, Elizabeth
    Yang, Yi-Chun Ou
    Carducci, Michael A.
    Tannock, Ian
    de Wit, Ronald
    Eisenberger, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3965 - 3970
  • [45] Role of mitoxantrone in the management of hormone-resistant metastatic prostate cancer
    Culine, S
    PROGRES EN UROLOGIE, 2002, 12 (01): : 31 - 35
  • [46] Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
    Vlachostergios, Panagiotis J.
    Niaz, Muhammad Junaid
    Sun, Michael
    Mosallaie, Seyed Ali
    Thomas, Charlene
    Christos, Paul J.
    Osborne, Joseph R.
    Molina, Ana M.
    Nanus, David M.
    Bander, Neil H.
    Tagawa, Scott T.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] PROSTATE-SPECIFIC ANTIGEN AND OTHER PROGNOSTIC FACTORS IN PATIENTS WITH HORMONE-RESISTANT PROSTATIC-CANCER UNDERGOING EXPERIMENTAL TREATMENT
    FOSSA, SD
    PAUS, E
    LINDEGAARD, M
    NEWLING, DWW
    BRITISH JOURNAL OF UROLOGY, 1992, 69 (02): : 175 - 179
  • [48] Introduction - Hormone-resistant prostate cancer
    Coulange, C
    Khoury, S
    PROGRES EN UROLOGIE, 2002, 12 (01): : 5 - 5
  • [49] Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer
    Kawaguchi, Gen
    Akazawa, Kohei
    Ikeda, Taro
    Ikeda, Yohei
    Hara, Noboru
    Nishiyama, Tsutomu
    SAGE OPEN MEDICINE, 2023, 11
  • [50] Using prostate-specific antigen doubling time in clinical practice
    Lee, Andrew K.
    D'Amico, Anthony V.
    BJU INTERNATIONAL, 2007, 100 (02) : 243 - 244
12345